New anti-MRSA drug optimal treatment strategy with Physiologically-based Pharmacokinetics/ Pharmacodynamics

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08950
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54030:Infectious disease medicine-related
• Research Institution: University of Toyama
• Principal Investigator: YAMAMOTO Yoshihiro 富山大学, 学術研究部医学系, 教授 (70452844)
• Co-Investigator(Kenkyū-buntansha): 辻 泰弘 日本大学, 薬学部, 教授 (20644339)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 抗菌薬適正使用 / 抗MRSA薬 / 薬物濃度 / 抗菌薬投与設計 / 特殊病態患者

Outline of Final Research Achievements

The objective of this study was to perform an external evaluation of linezolid population pharmacokinetic and pharmacodynamic models, to evaluate the predictive performance using an independent data set. Another aim was to offer an elegant environment for display and simulation of both the concentration and platelet count after linezolid administration.
We confirmed the transferability of population pharmacokinetic and pharmacodynamic models and also introduced application software based on our model for the therapeutic drug monitoring of linezolid.

Free Research Field

感染症

Academic Significance and Societal Importance of the Research Achievements

MRSA感染症患者に対して、特殊病態別にプロスペクティブに適用することが初めて可能となった。本研究で開発した抗菌薬投与設計ソフトウェアは抗MRSA薬を使用する全ての施設で利用可能な血中および組織中濃度を予測できるソフトウェアであり、抗MRSA薬の適正使用につながり、ひいては薬剤耐性(Antimicrobial Resistance: AMR)感染症の減少に貢献できると考えている。